The Impact of vCJD on a Safe Supply of Blood and Blood Products

Publisher： Karger

E-ISSN： 1660-3818|33|2|VII-VII

ISSN： 1660-3796

Source： Transfusion Medicine and Hemotherapy, Vol.33, Iss.2, 2006-11, pp. : VII-VII

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Safety of Blood and Blood Products with Regard to vCJD

By  

Transfusion Medicine and Hemotherapy, Vol. 33, Iss. 2, 2006-11 ,pp. : 13-17

Karger

Access to resources Recommend Favorite

Summary – Overall Blood Supply Strategy with Regard to vCJD

By  

Transfusion Medicine and Hemotherapy, Vol. 33, Iss. 2, 2006-11 ,pp. : 1-2

Karger

Access to resources Recommend Favorite

Possible Measures for Reduction the Potential Risk of vCJD Transmission by Blood and Blood Products

By  

Transfusion Medicine and Hemotherapy, Vol. 33, Iss. 2, 2006-11 ,pp. : 19-21

Karger

Access to resources Recommend Favorite

Overall Blood Supply Strategy with Regard to Variant Creutzfeldt-Jakob Disease (vCJD)

By  

Transfusion Medicine and Hemotherapy, Vol. 33, Iss. 2, 2006-11 ,pp. : III-IV

Karger

Access to resources Recommend Favorite

Report of the Working Group ‘Overall Blood Supply Strategy with Regard to Variant Creutzfeldt-Jakob Disease (vCJD)’

By  

Transfusion Medicine and Hemotherapy, Vol. 36, Iss. 1, 2009-02 ,pp. : 79-93

Karger

Access to resources Recommend Favorite